Nycomed announced today that Judge Jose L. Linares of the U.S. District Court for the District of New Jersey has confirmed the jury verdict in favor of Nycomed and Pfizer Inc. The decision upholds the jury verdict issued on April 23, 2010, confirming that the patent is valid and rejecting allegations by the defendants that the patent was invalid as obvious and invalid for double patenting. Against KUDCo, the US generic drug business of the Schwarz Pharma Group, which did not at-risk launch, final Judgment was entered as a result of Judge Jose L. Linares’ rulings. Continue Reading
Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Sandoz, Inc. regarding the production and sale of generic formulations of OPANA® ER (oxymorphone hydrochloride) Extended Release tablets. Continue Reading
Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patent listed by Abbott Laboratories and Fournier Laboratories Ireland Ltd. in connection with its TRILIPIX® (choline fenofibrate) delayed-release capsules, 135 mg and 45 mg. Continue Reading
Precision BioSciences, Inc., today announced that the United States Patent and Trademark Office (PTO) has issued non-final Actions Closing Prosecution in the reexamination proceedings for U.S. Pat. Nos. 6,833,252 (“the ‘252 patent”) and 7,214,536 (“the ‘536 patent”) that are owned by the Institut Pasteur and the Universite Pierre et Marie Cure (UPMC), and licensed to Cellectis, SA (ALCLS). For the second time, the PTO has rejected all claims under consideration as lacking novelty and/or as obvious in view of a variety of references, including many that were not provided to the patent examiners during prosecution by the patent applicants. Continue Reading
Sandata Technologies, Inc., a leading nationwide provider of information technology solutions to the home healthcare and social services communities, and Infocrossing, Inc. today announced the settlement of the patent infringement lawsuit between the two companies. Continue Reading
In an announcement today, Humanetics Corporation reported that its BIO 300 medical radiation countermeasure drug candidate has been issued a U.S. patent. The patent is assigned to the United States of America with Humanetics as the designated licensee. Continue Reading
Biomoda, Inc. (www.biomoda.com) was today awarded U.S. patent 7,670,799, entitled, “Composition and Method for Making 5, 10, 15, 20- Tetrakis (Carboxyphenyl) Porphine (TCPP)” directed to Biomoda’s proprietary TCPP formulation for cancer and pre-cancer cell identification and analysis and a method of making the TCPP formulation. Continue Reading
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Court of Appeals for the District of Columbia Circuit has ruled in Teva’s favor by overturning a July 31, 2009, district court decision which held that Teva forfeited 180-day marketing exclusivity for its generic versions of Merck’s antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium). Continue Reading
Amedica Corporation, a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today that it has been granted United States Patent No. 7,666,229 covering its novel ceramic-on-ceramic bearings for articulating joints used for total joint replacement and spinal disc applications. Continue Reading
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled “Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders” was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA). Continue Reading
